[
    {
        "id": "osp-11898",
        "type": "article-journal",
        "title": "Short-term efficacy and safety of intravitreal brolucizumab in diabetic macular edema: A retrospective interventional study",
        "author": [
            {
                "family": "Mal",
                "given": "Washoo"
            },
            {
                "family": "Al-Abri",
                "given": "Mohamed"
            },
            {
                "family": "Al-Fadhil",
                "given": "Nawal Ali"
            },
            {
                "family": "Jaju",
                "given": "Sanjay"
            },
            {
                "family": "Al-Riyami",
                "given": "Al Shaima Abdullah Suleiman"
            }
        ],
        "URL": "https://omanscience.com/en/articles/short-term-efficacy-and-safety-of-intravitreal-brolucizumab-in-diabetic-macular-edema-a-retrospective-interventional-study",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2025
                ]
            ]
        },
        "container-title": "Oman Journal of Ophthalmology",
        "volume": "18",
        "issue": "3",
        "page": "303-307",
        "DOI": "10.4103/ojo.ojo_231_25",
        "publisher": "Medknow Publications",
        "ISSN": "0974-620X",
        "abstract": "Objectives: This study aims to evaluate the efficacy and safety of intravitreal brolucizumab (IVBr), a novel antivascular endothelial growth factor agent, in the treatment of diabetic macular edema (DME) by assessing both functional (visual) and structural (anatomical) improvements.\n\nMaterials and methods: A retrospective, interventional study was conducted at the ophthalmology outpatient department of Sultan Qaboos University Hospital at University Medical City. A cohort of twenty patients (60 injections) with DME received three IVBr injections (6 mg/0.05 mL) over 18 weeks. This cohort consists of 10 male and 10 female patients, with a mean age of 57.1 years (range: 35-81; standard deviation [SD] 14.37). The best-corrected visual acuity (BCVA) was measured and recorded in equivalent logMAR. The subfoveal macular thickness (SFMT) was assessed with optical coherence tomography. Statistical analysis was carried out using paired t-test, and 95% confidence intervals were calculated to compare changes in outcomes, with a significance threshold set at P < 0.05.\n\nResults: The BCVA improved significantly from a baseline mean of logMar 0.36 (SD 0.7) to 0.22 (SD 0.5) after the third injection (P < 0.002). SFMT decreased from a mean of 517.75 μm (SD 160.27) to 287.95 μm (SD 101.31), P < 0.001. One patient developed intraocular inflammation, and no other major complications were observed. However, 35% of patients (n = 7) experienced inadequate visual improvement, attributed to underlying factors such as macular ischemia, retinal layer disorganization, disruption of the ellipsoid zone, and residual macular edema.\n\nConclusion: The study findings in this cohort demonstrated statistically significant improvement in BCVA and a substantial decrease in SFMT. However, more real-world studies are required to enhance the validation of this study's findings."
    }
]